Saturday, 31 October 2026European Markets

REC SILICON Stock Was Up By 28.15% On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with REC SILICON (RECSI.OL) rising 28.15% to kr10.54 on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI jumped 0.76% to kr1,411.02, after two successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

REC SILICON's last close was kr8.23, 51.39% below its 52-week high of kr16.93.

About REC SILICON

REC Silicon ASA, together with its subsidiaries, produces and sells silicon materials for the solar and electronics industries worldwide. It offers various Signature Silane gas, a pure form of silicon that produces product for fuel industries comprising specialty gases, including Dichlorosilane, Monochlorosilane, and Disilane for use in the manufacturing processes of flat panel displays, semiconductors, and solar cells; solar grade polysilicon, including NextSi used for multi crystalline and monocrystalline solar ingot and wafer production in the manufacturing of solar modules; and electronic grade polysilicon consisting of float zone-based devices are used in motor control and power conversion processes for hybrid and electric vehicles, wind energy, and high voltage transmission, 5G communications, high-speed trains, internet of things, and big data, as well as Czochralski for manufacturing of semiconductor wafers used in memory processors, optics, and micro electromechanical systems. The company was formerly known as Renewable Energy Corporation ASA and changed its name to REC Silicon ASA in October 2013. REC Silicon ASA was founded in 1996 and is headquartered in Lysaker, Norway.

Earnings Per Share

As for profitability, REC SILICON has a trailing twelve months EPS of kr-0.32.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -309.33%.

Volatility

REC SILICON's last week, last month's, and last quarter's current intraday variation average was 8.29%, 0.81%, and 3.27%.

REC SILICON's highest amplitude of average volatility was 8.65% (last week), 4.06% (last month), and 3.27% (last quarter).

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is a negative 233.3% and a negative 95.2%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 155.1M for the twelve trailing months.

More news about REC SILICON (RECSI.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com